When was Acrongenomics founded?

Acrongenomics was founded in 1999 and raised its 1st funding round 8 years after it was founded.

Where is Acrongenomics located?

Acrongenomics is headquartered in London, United Kingdom.

How many employees does Acrongenomics have?

As of Apr 30, 2026, the latest employee count at Acrongenomics is 1.

Is Acrongenomics a funded company?

Acrongenomics is a funded company, having raised a total of $***** in its 1st and only funding round, a Post IPO round on May 15, 2007.

When was the latest funding round of Acrongenomics?

Acrongenomics' latest funding was a $***** Post IPO round on May 15, 2007, with participation from 0 investor. Its primary sector is Cardiac and Vascular Disorders. Globally, the Cardiac and Vascular Disorders sector has seen $1.11B in funding in 2026 to date.

Where does Acrongenomics rank among its competitors?

Acrongenomics ranks 80th amongst 86 active competitors, of which 22 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was SmartHealth, which secured $300K in Nov, 2024.

Who are the top competitors of Acrongenomics?

Acrongenomics' top competitors include GEN inCode, Boston Heart Diagnostics and SmartHealth. Among them, SmartHealth secured the most recent funding round in November, 2024.

Acrongenomics - 2026 Company Profile, Funding & Competitors

Acrongenomics is a late stage company based in London (United Kingdom), founded in 1999. It operates as a Lab-on-chip device for point of care molecular diagnostics and drug discovery. Acrongenomics has raised an undisclosed amount in funding. The company has 86 active competitors, including 22 funded and 18 that have exited. Its top competitors include companies like GEN inCode, Boston Heart Diagnostics and SmartHealth.

Company Details

Acron Genomics develops point-of-care molecular diagnostics based on its platform technology that integrates lab-on-chip technology with light-emitting polymers that enable rapid testing across a wide range of diseases. The company has a stake in Molecular Vision, with which it collaborates on its product development and R&D efforts, including discovery and development of biomarkers to be implemented in the diagnostic platform. The company intends to develop applications in cardiovascular disease, kidney tests, STD diagnostics, and substance abuse. Apart from its interest in diagnostics, the company is also developing an essential oil compound derived from plant extracts called "Compound X" as an antilipidemic therapeutic to lower both the cholesterol and the triglyceride serum levels to reduce the risk of coronary artery disease.

Website: www.acrongenomics.com/main/
Email ID: *****@acrongenomics.com

Key Metrics

Founded Year

1999

Location

London, United Kingdom

Stage

Late Stage

Latest Funding Round

Post IPO, May 15, 2007, $*****

Ranked

80^th among 86 active competitors

Employee Count

1 as on Apr 30, 2026

Similar Companies

GEN inCode & 113 more

View Acrongenomics' full profile

Acrongenomics has raised funding over 1 round.

Here is the list of recent funding rounds of Acrongenomics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 15, 2007	8842433	Post IPO	2711438	1051980	9795108	9762802

Access funding benchmarks and valuations. Sign up today!

View details of Acrongenomics's funding rounds and investors

Acrongenomics' employee count trend

Acrongenomics has 1 employees as of Apr 26. Here is Acrongenomics's employee count trend over the years:

Uncover Acrongenomics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Acrongenomics include GEN inCode, Boston Heart Diagnostics and SmartHealth. Here is the list of Top 10 competitors of Acrongenomics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	GEN inCode 2018, Manchester (United Kingdom), Public	Developer of precison medicines by combining genetic and clinical data for cardiac disease monitoring	$5.46M	Downing, Maven Capital Partners & 4 others	57/100
2nd	Boston Heart Diagnostics 2007, Framingham (United States), Acquired	Developer of diagnosis for personalized care for cardiovascular diseases	$10.3M	Bain Capital Ventures, Silversmith Capital Partners ... & 8 others	51/100
3rd	SmartHealth 1979, Irvine (United States), Series B	Developer precision diagnostics for vascular, metabolic, and oncological diseases	$17.3M	-	49/100
4th	Realview Imaging 2008, Yokneam Illit (Israel), Series C	Provides 3D holographic display based solutions for medical imaging applications	$25M	OurCrowd, ADIP & 10 others	49/100
5th	Myocardial Solutions 2002, Morrisonville (United States), Series B	Provider of MRI-based diagnostic software for cardiac disease	$33.9M	Pond Capital	49/100
6th	Zora Biosciences 2016, Espoo (Finland), Funding Raised	Provider of diagnostic solutions for cardiovascular diseases and cancer	-	Voima Ventures, Europa	48/100
7th	Proxim Diagnostics 2010, Sunnyvale (United States), Series B	Developer of a handheld immunodiagnostic device for cardiac vascular diseases	$22.9M	BioMerieux, UCLA Ventures & 1 others	46/100
8th	Prevencio 2006, Kirkland (United States), Series B	Protein-based diagnostics for cardiovascular diseases	$5.68M	Gershon Capital	46/100
9th	Diadexus 1997, San Francisco (United States), Acquired	Innovating clinical diagnostics with advanced enzyme and immunoassay technologies	$49.2M	Brookside Capital, Scale Venture Partners ... & 4 others	45/100
10th	Arineta 2006, Caesarea (Israel), Series A	Developing imaging solutions for cardiac care	$10M	-	44/100
80th	Acrongenomics 1999, London (United Kingdom), Late Stage	Lab-on-chip device for point of care molecular diagnostics and drug discovery	-	-	22/100